Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 10:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 249 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pneumococcal Conjugate Vaccine Clear all
Recruiting Phase 4 Interventional

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

NCT06829238
View directory record Official record
Conditions
Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Interventions
Metformin, Placebo, Jynneos, Capvaxvie
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

NCT05831124
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control, Standard dose multivalent pneumococcal conjugate vaccine control
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Hialeah, Florida • Hollywood, Florida • Columbia, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

NCT02097589
View directory record Official record
Conditions
Healthy Controls
Interventions
Atorvastatin, Pneumovax 23, Placebo (lactose pill)
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 20, 2026, 10:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01312389
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-L/Montanide ISA 51 VG, Ampligen, Prevnar
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 20, 2026, 10:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of PCV on Disease and Colonization Among Native American Communities

NCT01083459
View directory record Official record
Conditions
Pneumococcal Nasopharyngeal Colonization, Invasive Pneumococcal Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
7 Months and older
Enrollment
6,628 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Whiteriver, Arizona • Gallup, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Sep 20, 2026, 10:33 PM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

NCT03893448
View directory record Official record
Conditions
Pneumococcal Infections, Pneumococcal Vaccines
Interventions
V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
1,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 20, 2026, 10:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Effect of Obesity on Immune Response to Pneumovax 23

NCT02471014
View directory record Official record
Conditions
Obesity
Interventions
Pneumovax 23, Blood tests, Questionnaires
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 20, 2026, 10:33 PM EDT
Completed No phase listed Observational

Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

NCT01128439
View directory record Official record
Conditions
Invasive Pneumococcal Disease
Interventions
No intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

NCT00046852
View directory record Official record
Conditions
Infection, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects

NCT00706550
View directory record Official record
Conditions
HIV Infections
Interventions
(PV) 23-valent pneumococcal polysaccharide vaccine, Placebo
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 20, 2026, 10:33 PM EDT
Completed No phase listed Observational Results available

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

NCT05794191
View directory record Official record
Conditions
HIV, Pneumonia, Infections, Pneumococcal
Interventions
Vaccine Administration
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350,399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 20, 2026, 10:33 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

NCT02266277
View directory record Official record
Conditions
Influenza, Infections, Pneumococcal
Interventions
Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call, Arm 5: IVR call
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 20, 2026, 10:33 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

NCT07300267
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1), PCV20 (Stage 2)
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Months to 15 Months
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
14
States / cities
Madera, California • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 20, 2026, 10:33 PM EDT
Recruiting Phase 3 Interventional

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

NCT07247188
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
PCV21, 20vPCV
Biological
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Omaha, Nebraska • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

NCT04382326
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,997 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
105
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00445484
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
pneumococcal polyvalent vaccine, lenalidomide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2015 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

NCT02124161
View directory record Official record
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Interventions
13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 20, 2026, 10:33 PM EDT
Recruiting Phase 4 Interventional

Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

NCT07135427
View directory record Official record
Conditions
Alpha 1-Antitrypsin, COPD, Antibody Deficiency
Interventions
20-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

NCT00772928
View directory record Official record
Conditions
Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Interventions
Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
23
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 20, 2026, 10:33 PM EDT
Completed No phase listed Observational Results available

Impact of Prevnar 13 on Ear Infections in Children

NCT01272999
View directory record Official record
Conditions
Acute Otitis Media, Mastoiditis
Interventions
No intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 20, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

NCT03692871
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
22
States / cities
Downey, California • Huntington Beach, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 20, 2026, 10:33 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06736041
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,714 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
66
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 20, 2026, 10:33 PM EDT